BET Proteins as _targets for Anticancer Treatment
- PMID: 29263030
- DOI: 10.1158/2159-8290.CD-17-0605
BET Proteins as _targets for Anticancer Treatment
Abstract
Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression and are involved in cancer pathogenesis. Over the last years, several BET inhibitors have been developed and clinically tested. Results from the first clinical trials show limited single-agent activity in a small subset of patients with hematologic malignancies and in NUT carcinoma. Adverse events have been observed and may limit treatment compliance. Here, we review the preclinical rationale for _targeting BET proteins in cancer and the preliminary results from clinical trials, and outline future directions for the use of BET inhibitors as antitumor agents.Significance: BET inhibitors represent a new class of anticancer agents. Results from the first clinical trials confirm the antitumor potential of BET inhibitors, but their efficacy as single agents seems to be limited. Based on preclinical data, combination therapies with other anticancer agents and the development of a new generation of compounds may open new possibilities for _targeting BET proteins as effective anticancer strategies. Cancer Discov; 8(1); 24-36. ©2017 AACR.
©2017 American Association for Cancer Research.
Similar articles
-
The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8326-31. doi: 10.1073/pnas.1424220112. Epub 2015 Jun 25. Proc Natl Acad Sci U S A. 2015. PMID: 26111795 Free PMC article.
-
Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).Expert Opin Investig Drugs. 2017 Jul;26(7):803-811. doi: 10.1080/13543784.2017.1335711. Epub 2017 Jun 9. Expert Opin Investig Drugs. 2017. PMID: 28541716 Review.
-
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.Theranostics. 2016 Jan 1;6(2):219-30. doi: 10.7150/thno.13178. eCollection 2016. Theranostics. 2016. PMID: 26877780 Free PMC article.
-
_targeting BET bromodomains for cancer treatment.Epigenomics. 2015;7(3):487-501. doi: 10.2217/epi.14.91. Epigenomics. 2015. PMID: 26077433 Review.
-
Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics.Curr Opin Oncol. 2021 Sep 1;33(5):526-531. doi: 10.1097/CCO.0000000000000763. Curr Opin Oncol. 2021. PMID: 34280171 Review.
Cited by
-
BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation.Sci Adv. 2021 May 26;7(22):eabf5374. doi: 10.1126/sciadv.abf5374. Print 2021 May. Sci Adv. 2021. PMID: 34039605 Free PMC article.
-
BRD4 modulates vulnerability of triple-negative breast cancer to _targeting of integrin-dependent signaling pathways.Cell Oncol (Dordr). 2020 Dec;43(6):1049-1066. doi: 10.1007/s13402-020-00537-1. Epub 2020 Oct 2. Cell Oncol (Dordr). 2020. PMID: 33006750 Free PMC article.
-
TIF1 Proteins in Genome Stability and Cancer.Cancers (Basel). 2020 Jul 28;12(8):2094. doi: 10.3390/cancers12082094. Cancers (Basel). 2020. PMID: 32731534 Free PMC article. Review.
-
The current status and future trends of BET research in oncology.Heliyon. 2024 Aug 24;10(17):e36888. doi: 10.1016/j.heliyon.2024.e36888. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39281429 Free PMC article.
-
_targeting radioresistance and replication fork stability in prostate cancer.JCI Insight. 2022 May 9;7(9):e152955. doi: 10.1172/jci.insight.152955. JCI Insight. 2022. PMID: 35349486 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
